Duke Univ., Durham, NC (United States). School of Medicine. Duke Human Vaccine Inst.; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Medicine; DOE/OSTI
Fred Hutchinson Cancer Research Center, Seattle, WA (United States). Statistical Center for HIV/AIDS Research and Prevention. Vaccine and Infectious Disease Division
Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics
Duke Univ., Durham, NC (United States). School of Medicine. Duke Human Vaccine Inst.; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Medicine
Rutgers Univ., Newark, NJ (United States). New Jersey Medical School. Public Health Research Inst.
Thailand Ministry of Public Health, Bangkok (Thailand). Department of Disease Control
Mahidol Univ., Bangkok (Thailand). Vaccine Trial Center
Armed Forces Research Inst. of Medical Sciences, Bangkok (Thailand)
Univ. of California, Santa Cruz, CA (United States). Dept. of Biomedical Engineering
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD (United States); Walter Reed Army Inst. of Research, Silver Spring, MD (United States). US Military HIV Research Program
Univ. of Lusanne (Switzerland). Lausanne Univ. Hospital. Swiss Vaccine Research Inst. Dept. of Medicine. Service of Infecitous Diseases. Service of Immunology and Allergy
Icahn School of Medicine at Mount Sinai, New York, NY (United States)
Duke Univ., Durham, NC (United States). School of Medicine. Duke Human Vaccine Inst.; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Medicine; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Immunology
Duke Univ., Durham, NC (United States). School of Medicine. Duke Human Vaccine Inst.; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Surgery
Duke Univ., Durham, NC (United States). School of Medicine. Duke Human Vaccine Inst.; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Immunology; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Surgery; Duke Univ., Durham, NC (United States). School of Medicine. Dept. of Molecular Genetics and Microbiology
Induction of broadly cross-reactive antiviral humoral responses with the capacity to target globally diverse circulating strains is a key goal for HIV-1 immunogen design. A major gap in the field is the identification of diverse HIV-1 envelope antigens to evaluate vaccine regimens for binding antibody breadth. In this study, we define unique antigen panels to map HIV-1 vaccine-elicited antibody breadth and durability. Diverse HIV-1 envelope glycoproteins were selected based on genetic and geographic diversity to cover the global epidemic, with a focus on sexually acquired transmitted/founder viruses with a tier 2 neutralization phenotype. Unique antigenicity was determined by nonredundancy (Spearman correlation), and antigens were clustered using partitioning around medoids (PAM) to identify antigen diversity. Cross-validation demonstrated that the PAM method was better than selection by reactivity and random selection. Analysis of vaccine-elicited V1V2 binding antibody in longitudinal samples from the RV144 clinical trial revealed the striking heterogeneity among individual vaccinees in maintaining durable responses. These data support the idea that a major goal for vaccine development is to improve antibody levels, breadth, and durability at the population level. Elucidating the level and durability of vaccine-elicited binding antibody breadth needed for protection is critical for the development of a globally efficacious HIV vaccine.
Yates, Nicole L., et al. "HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees." Journal of Virology, vol. 92, no. 8, Mar. 2018. https://doi.org/10.1128/jvi.01843-17
Yates, Nicole L., deCamp, Allan C., Korber, Bette T., et al., "HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees," Journal of Virology 92, no. 8 (2018), https://doi.org/10.1128/jvi.01843-17
@article{osti_1626074,
author = {Yates, Nicole L. and deCamp, Allan C. and Korber, Bette T. and Liao, Hua-Xin and Irene, Carmela and Pinter, Abraham and Peacock, James and Harris, Linda J. and Sawant, Sheetal and Hraber, Peter and others},
title = {HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees},
annote = {Induction of broadly cross-reactive antiviral humoral responses with the capacity to target globally diverse circulating strains is a key goal for HIV-1 immunogen design. A major gap in the field is the identification of diverse HIV-1 envelope antigens to evaluate vaccine regimens for binding antibody breadth. In this study, we define unique antigen panels to map HIV-1 vaccine-elicited antibody breadth and durability. Diverse HIV-1 envelope glycoproteins were selected based on genetic and geographic diversity to cover the global epidemic, with a focus on sexually acquired transmitted/founder viruses with a tier 2 neutralization phenotype. Unique antigenicity was determined by nonredundancy (Spearman correlation), and antigens were clustered using partitioning around medoids (PAM) to identify antigen diversity. Cross-validation demonstrated that the PAM method was better than selection by reactivity and random selection. Analysis of vaccine-elicited V1V2 binding antibody in longitudinal samples from the RV144 clinical trial revealed the striking heterogeneity among individual vaccinees in maintaining durable responses. These data support the idea that a major goal for vaccine development is to improve antibody levels, breadth, and durability at the population level. Elucidating the level and durability of vaccine-elicited binding antibody breadth needed for protection is critical for the development of a globally efficacious HIV vaccine.},
doi = {10.1128/jvi.01843-17},
url = {https://www.osti.gov/biblio/1626074},
journal = {Journal of Virology},
issn = {ISSN 0022-538X},
number = {8},
volume = {92},
place = {United States},
publisher = {American Society for Microbiology},
year = {2018},
month = {03}}